Stephen Liu: Perioperative osimertinib for resectable EGFR NSCLC
Stephen Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:
“Perioperative osimertinib for resectable EGFR NSCLC in the single institution NORA trial, JTO & JTO CRR from Jii Bum Lee et al.
After 56d of neoadjuvant osimertinib, RR 44%, MPR 24%, pCR rate 0%. mDFS not yet reached after 31m.”
Neoadjuvant and adjuvant osimertinib in stage IA-IIIA, EGFR-mutant non-small cell lung cancer (NORA)
Authors: Jii Bum Lee, Su-Jin Choi, Hyo Sup Shim, Byung Jo Park, Chang Young Lee, Sumedha Sudhaman, Sharlene Velichko, Min Hee Hong, Byoung Chul Cho, Sun Min Lim
Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center.
As a board-certified medical oncologist specializing in lung cancer and drug development,
Dr. Liu is known for his expertise in advanced thoracic malignancies. His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer.
Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023